Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online April 19, 2007
Diabetes 56:1842-1849, 2007
DOI: 10.2337/db06-1198
© 2007 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db06-1198v1
db06-1198v2
db06-1198v3
56/7/1842    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scalia, R.
Right arrow Articles by Sharma, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scalia, R.
Right arrow Articles by Sharma, K.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hyperglycemia Is a Major Determinant of Albumin Permeability in Diabetic Microcirculation

The Role of µ-Calpain

Rosario Scalia1, Yulan Gong1, Brett Berzins1, Li Juan Zhao1, and Kumar Sharma2

1 Department of Molecular Physiology and Biophysics, Jefferson Medical College, Philadelphia, Pennsylvania
2 Center for Novel Therapies for Kidney Disease, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania

Address correspondence and reprint requests to Rosario Scalia, MD, PhD, Department of Molecular Physiology and Biophysics, Jefferson Medical College, Thomas Jefferson University, 1020 Locust St., Philadelphia, PA 19107-6799. E-mail: rosario.scalia{at}jefferson.edu

Abbreviations: IVM, intravital microscopy; ODN, oligodeoxynucleotide; PKC, protein kinase C; PMN, polymorphonuclear; Vrbc, red blood cell velocity; ZLLal, benzyloxycarbonyl-Leu-leucinal


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Increased permeability to albumin is a well-known feature of diabetic microvasculature and a negative prognostic factor of vascular complications. The mechanisms responsible for loss of the physiological albumin barrier in diabetic organs remain only partially understood. We have recently demonstrated that the protease µ-calpain is activated in hyperglycemia, which causes endothelial dysfunction and vascular inflammation. In the present study, we investigated whether µ-calpain is involved in the hyperpermeability of the diabetic vasculature. We also investigated the mechanistic roles of hyperglycemia and leukocyte adhesion in this process. Albumin permeability in the intact microcirculation of the Zucker diabetic fatty (ZDF) rat was quantified by intravital microscopy. Extravasation of albumin in the microcirculation of ZDF rats was significantly increased when compared with nondiabetic Zucker lean (ZL) rats. Microvascular albumin leakage was prevented by either antisense depletion of µ-calpain or pharmacological inhibition of calpain in vivo. Calpain inhibition also attenuated urinary albumin excretion in ZDF rats. Glucose concentrations in the range of those found in the blood of ZDF rats increased albumin permeability in nondiabetic ZL rats. Thus, this demonstrates a mechanistic role for hyperglycemia in the hypermeability of diabetes. Depletion of polymorphonuclear leukocytes in vivo failed to prevent glucose-induced hypermeability, which suggests that hyperglycemia can disrupt the physiological endothelial cell barrier of the microcirculation, even in the absence of increased overt leukocyte-endothelium interactions.

Hyperglycemia is associated with vascular complications. Because of its strategic position between blood and the vascular wall, the vascular endothelium is a primary target of the ravaging actions of hyperglycemia. Accordingly, there is consensus that hyperglycemia causes chronic endothelial dysfunction (1,2). Several studies have shown that increased endothelial permeability is an early manifestation of endothelial dysfunction in diabetes (3–5). Alterations in the physiological endothelial cell barrier are likely to impair organ function, due to the accumulation of plasma macromolecules in the interstitial compartment of body organs (6). Therefore, microalbuminuria is now viewed as an important clinical parameter and therapeutic target for the treatment of vascular complications in diabetic patients (7). However, the molecular mechanism(s) responsible for endothelial hyperpermeability in diabetes remains largely unknown, which limits effective therapeutic interventions.

Calpains are a family of calcium-dependent cysteine proteases found in mammals and many lower organisms (8). We have reported that acute experimental hyperglycemia, as well as diabetes, upregulate the endothelial-expressed µ-calpain isoform in the microcirculation (a process that results in endothelial dysfunction and abnormal leukocyte trafficking) (9,10). Other studies have reported that inhibition of calpain activity improves organ function in diabetic animal models (11,12) and in acute cardiovascular events (13). In vitro studies have now implicated calpains in the regulation of endothelial cell barrier (14,15).

This study tests the hypothesis that calpain is involved in the abnormal permeability of the endothelial cell barrier of Zucker diabetic fatty (ZDF) rats, a relevant animal model of type 2 diabetes. We also evaluated the roles of calpain and leukocyte-endothelium interaction in the hyperpermeability of hyperglycemia, and we studied whether the inhibitory effect of calpain inhibition on albumin permeability is mediated through downregulation of leukocyte-endothelium interaction in vivo.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Experimental animal models of hyperglycemia.
All animal procedures were approved by the Thomas Jefferson University institutional animal care and use committee. We used 10- to 14-week-old male ZDF rats and age-matched nondiabetic Zucker lean (ZL) rats (Charles River Laboratories; Noblesville, IN). At this age, ZDF rats develop hyperglycemia with hypoinsulinemia (16), which permits study of the effect of chronic hyperglycemia alone on microvascular function. Moreover, ZDF rats have increased vascular permeability (17), and increased calpain activity is in the microcirculation (9). Rats were randomly assigned to the one of the following experimental groups: 1) ZL rats injected with vehicle; 2) ZDF rats injected with vehicle; 3) ZDF rats treated with 1 mg/kg sense nucleotide to µ-calpain (once a day for 4 consecutive days); 4) ZDF rats treated with 1 mg/kg antisense nucleotide to µ-calpain (once a day for 4 consecutive days); or 5) ZDF rats injected intraperitoneally with 27 µg/kg calpain inhibitor benzyloxycarbonyl-Leu-leucinal (ZLLal) (once a day for 4 consecutive days).

Acute experimental hyperglycemia of the mesenteric microvasculature in nondiabetic ZL rats was induced by a single intraperitoneal injection of 25 mmol/l D-glucose (Sigma, Saint Louis, MO), administered 12 h before study. We and others have demonstrated that this procedure triggers a sustained inflammatory response in mesenteric postcapillary venules, which lasts over a 24-h period (18,19). L-glucose (Sigma) was used at the concentration of 25 mmol/l as a control to exclude nonspecific osmolarity effects of D-glucose. In these experiments, upregulation of calpain activity was prevented by pretreatment of rats with a single intraperitoneal injection of 27 µg/kg ZLLal, as previously described by our laboratory (10).

In vivo microcirculatory parameters.
Quantitative intravital microscopy (IVM) of mesenteric microcirculation was used to measure vessel diameter, venular wall shear rates, leukocyte adhesion, vascular density, and albumin permeability in all experimental groups of rats.

Preparation of animals for IVM.
Following anesthesia with 80 mg/kg i.p. pentobarbital, rats were prepared for IVM studies, as previously described (9). Briefly, four distal loops of ileal tissue, exteriorized through a midline incision laparotomy, were superfused with 37°C Krebs-Henseleit buffer in an IVM Plexiglas chamber attached on the stage of an Eclipse 80si microscope (Nikon). Three to four relatively straight unbranched segments of postcapillary venules with lengths of >100 µm and diameters between 25 and 40 µm were randomly studied in each rat. Observation of the mesenteric microcirculation was made with a 20x salt water–immersion lens. Images were projected by high-resolution intensified video cameras (Evolution QEi or Photometric Cascade 512B) on to a high-resolution color video monitor (Multiscan 200-sf; Sony), and the image was recorded with a digital DVD recorder (Panasonic DMR-10). All data were analyzed using computerized imaging software (Image Pro Plus version 5.1; Media Cybernetics, Silver Spring, MD) on a Pentium-based International Business Machines (IBM)compatible computer.

Venular diameter.
Venular diameter was measured online using a video caliper and Image Pro Plus version 5.1.

Erythrocyte velocity and venular wall shear rates.
Red blood cell velocity (Vrbc) was measured online using an optical Doppler velocimeter (Microcirculation Research Institute, College Station, TX). Vrbc and venular diameter (D) were used to calculate the venular wall interfacial sheer rate ({gamma}) by using the formula: {gamma} = 4.9 x 8 x (venular mean/D), where venular mean = Vrbc/1.6. (20).

Leukocyte adhesion.
The number of adherent leukocytes was determined offline during video playback analysis, as previously described (9). Baseline leukocyte adherence was defined as the number of cells that remain stationary for >30 s in 100 µm of vessel length.

Vascular density.
Microvascular density was measured in random segments of the visceral peritoneum of three predefined ileal loops (i.e., the three most distal loops of ileum), according to a previously described method (21) (found in an online appendix "Supplemental Methods" [at http://dx.doi.org/10.2337/db06-1198]).

Vascular permeability.
The permeability index of postcapillary venules was determined by intravital fluorescent microscopy using Texas Red–labeled albumin (15 mg/kg body wt) (TR-BSA; Molecular Probes), according to a previously described technique (Supplemental Methods) (22).

Urinary albumin excretion.
ZL and ZDF rats and ZDF rats given 27 µg · kg–1 · day–1 ZLLal for 4 consecutive days were placed in metabolic cages for a 24-h collection of urine. Urinary albumin excretion was analyzed with the Nephrat enzyme-linked immunosorbent assay (Exocell, Philadelphia, PA). Briefly, 24-h urine samples stored at –20°C were thawed and centrifuged at 10,000 rpm for 15 min to remove debris, and samples were assayed according to the manufacturers’ guide. Urinary creatinine levels were measured using the Creatinine Companion kit (Exocell). All albumin values were normalized to those of creatinine and expressed as milligrams albumin to milligrams creatinine.

Quantification of calpain activity.
Calpain activity was measured using a standard fluorescent assay for calpain (23) that was recently adapted by our laboratory to measure calpain activity in vascular tissue (9). Briefly, highly vascularized mesenteric segments were isolated with the aid of a dissecting microscope. Tissue was snap frozen in liquid nitrogen and prepared for biochemical analyses of calpain activity, as previously described (24). For separation of soluble and total particulate mesentery fractions, the supernatant was subjected to 60-min centrifugation at 100,000g. Calpain activity in cytosolic tissue extracts was determined using the highly sensitive fluorescent calpain substrate Succ-LLVY-AMC (N-succinyl-L-leucyl-L-valyl-L-tyrosine-7-amino-4-methylcoumarin) (Molecular Probes, Eugene, OR), at the concentration of 30 µmol/l. Mean fluorescence signals were measured using a Bio-Tek FLx 800 microplate fluorescence reader (Bio-Tek, Winooski, VT) (excitation {lambda} 360 nm and emission {lambda} 460 nm). Calpain activity levels in all experimental groups of rats were expressed as percentage change from control values.

Inhibition of µ-calpain activity
Pharmacological inhibition.
The calpain inhibitor ZLLal (Biomol Research Laboratories, Plymouth Meeting, PA) was used because it is the highest selectivity for calpains over other proteosomal enzymes (25) and because of its efficacy in preventing activation of µ-calpain in the microvasculature in response to acute hyperglycemia (10) and diabetes (9). ZLLal was dissolved in a final ethanol concentration of 0.01%. In control experiments, intraperitoneal injection of saline (0.9% NaCl) containing 0.01% ethanol to rats did not affect microvascular parameters (data not shown).

Antisense depletion of µ-calpain.
We used sense and antisense oligodeoxynucleotide (ODN) corresponding to exon 12 of µ-calpain. Sense: 5' ATGCTTCTCGGGCACAAT 3'; antisense: 5' ATTGTGCCCGAGAAGCAT 3' (MWG Biotech, High Point, NC). The sense ODN was used as an inactive control to rule out nonspecific effects of ODN treatment. Three to five bases at both the 5' and 3' ends were modified with phosphorothioate to increase ODN stability in vivo; thus, pharmakinetics and tissue distribution improved. ODNs were dissolved in sterile saline (0.9%) and administered to rats via intraperitoneal injection. We have previously demonstrated the efficacy of the oligonucleotides used in this study in suppressing µ-calpain expression levels in rat mesenteric microvascular endothelial cells (9).

Analysis of µ-calpain expression level.
The extent and localization of µ-calpain expression after antisense therapy were confirmed by Western blot analysis and by immunohistochemistry, respectively. For immunoblot studies, highly vascularized mesenteric segments were isolated with the aid of a dissecting microscope. Tissue was snap-frozen in liquid nitrogen and homogenized as previously described (10). Briefly, calpain expression levels were studied using an antibody against the stable Domain IV (RP3 calpain-1; Triple Point Biologics, Portland, OR) of the large subunit of µ-calpain. Proteins were detected by chemiluminescence (Supersignal West Pico; Pierce, Rockford, IL) and quantified by laser densitometry (Molecular Dynamics Personal Densitometer; Molexular Dynamics, Piscataway, NJ).

In additional studies, at the completion of IVM experiments, sections of mesentery and ileum were fixed in vivo, dehydrated in graded acetone washes, and embedded in plastic, as previously described (9). Briefly, immunohistochemical localization of µ-calpain was accomplished using an antibody against Domain IV of µ-calpain and the avidin/biotin immunoperoxidase technique.

Depletion of polymorphonuclear leukocytes in vivo.
In some animals, the circulating pool of polymorphonuclear (PMN) leukocytes was depleted by intraperitoneal administration of 1 mg/kg antineutrophil serum (Accurate Chemical and Scientific Corporation, Wesbury, NY), according to a previously described method (26).

Hematologic parameters.
Tail vein blood was used to obtain blood glucose levels and peripheral neutrophils counts. Blood glucose levels were measured using an Accu-Chek glucose meter (Roche Diagnostic, Indianapolis, IN). The peripheral neutrophil counts were evaluated manually using a Neubauer chamber, according to standard hematology procedures.

Data analysis.
Data are presented as means ± SEM and compared by ANOVA with post hoc analysis by Fisher's corrected t test. P values ≤0.05 were considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Inhibition of calpain activity does not affect hyperglycemia in ZDF rats.
Compared with ZL rats, ZDF rats showed fasting hyperglycemia in the range of 23 ± 4.75 mmol/l (P < 0.01 vs. ZL rats; blood glucose levels 5.4 ± 0.7 mmol/l). Blood glucose levels were not changed by pharmacological inhibition of calpain activity with ZLLal or by µ-calpain ODN therapy (blood glucose levels 24 ± 3.75 mmol/l and 22 ± 6.7 mmol/l, respectively; P > 0.05 vs. untreated ZDF rats).

Downregulation of µ-calpain reduces the albumin hypermeability of the diabetic microvasculature.
We measured albumin permeability in intact postcapillary venules of ZDF rats by IVM because postcapillary venules exhibit dramatic changes in permeability in response to hyperglycemia and diabetes (5). Figure 1A (left panel) demonstrates that the microcirculation of ZDF rats is significantly more permeable to albumin than that of ZL rats. A 4-day treatment of ZDF rats with the calpain inhibitor ZLLal significantly attenuated albumin permeability in the diabetes microcirculation (Fig. 1A).


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		FIG. 1. µ-Calpain is responsible for increased albumin permeability in the diabetic vasculature. A: The average permeability index to Texas Red–labeled albumin that was calculated during IVM studies in mesenteric postcapillary venules of nondiabetic ZL rats and diabetic ZDF rats. µ-Calpain activity was blocked by either pharmacological inhibition with ZLLal or antisense ODN depletion. Control sense nucleotides were also given to the ZDF rats. B: Calpain activity levels in tissue extracts of vascular segments of mesenteries obtained from all groups of rats. Calpain activity in cytosolic tissue extracts was determined using the highly sensitive fluorescent calpain substrate Succ-LLVY-AMC using a microplate fluorescence reader. Calpain activity levels in all experimental groups of rats were expressed as percentage change from control values. C: Correlation analyses between calpain activity and the permeability index in nondiabetic ZL ({blacksquare}) and diabetic ZDF ({square}) rats. Data are expressed as means ± SEM. n = 6–8 rats (average) in each group.

 
Both the m-calpain and µ-calpain isoforms are constitutively expressed in endothelial cells (27), but the µ-calpain isoform has been recently linked to microvascular alterations of hyperglycemia (9,10). Accordingly, we used antisense depletion of µ-calpain to confirm whether µ-calpain is the calpain isoform largely responsible for increased albumin permeability in diabetes. Intraperitoneal delivery of µ-calpain antisense ODN for 4 consecutive days attenuated albumin permeability in the mesenteric microcirculation of ZDF rats. In contrast, administration of sense ODN sequences failed to prevent albumin leakage (Fig. 1A).

These data demonstrate a role for the µ-calpain isoform in the hypermeability of the diabetic endothelium and indicate µ-calpain as the molecular target of the endothelial protective action of pharmacological calpain inhibition in vivo.

Biochemical analyses of calpain activity positively correlated with vascular permeability data (Fig. 1B). Compared with ZL rats, ZDF rats showed a 40% increase in calpain activity in highly vascularized regions of the mesentery that were also abnormally leaky to albumin (Fig. 1B). A comparable degree of calpain activity inhibition was observed following intraperitoneal delivery of either µ-calpain antisense ODN or the calpain inhibitor ZLLal. This indicates µ-calpain as the calpain isoform responsible for increased endothelial calpain activity under our experimental conditions. Moreover, linear regression modeling confirmed that increased calpain activity positively correlates with increased vascular permeability in the diabetic microcirculation of the ZDF rat (Fig. 1C).

Immunoblot analyses of µ-calpain demonstrated a threefold reduction in µ-calpain expression levels in ZDF rats given antisense ODN (Fig. 2A and B). Immunohistochemical staining confirmed that µ-calpain expression in the intestinal microvessels of ZDF rats was almost completely suppressed by antisense ODN therapy (Fig. 2C and E). In contrast, baseline staining for µ-calpain was detected in the endothelial lining of blood vessels and in the extravascular space of intestinal tissue obtained from control ZDF rats and ZDF rats given sense ODN (Fig. 2C and D).


Figure 2
View larger version (57K):
[in this window]
[in a new window]

  		FIG. 2. Intraperitoneal injection of antisense oligonucleotides for 4 consecutive days effectively suppresses µ-calpain expression in the rat intestinal microvasculature. A primary antibody against µ-calpain Domain IV was used to quantify total µ-calpain content in vascularized tissue extracts of the rat mesentery (Immunoblot). A and B: Graphs demonstrate densitometric analysis of µ-calpain Domain IV, after normalization to the expression levels of ß-actin. Immunohistochemistry confirmed reduced expression level of µ-calpain in the vascular wall of venules, in addition to the perivascular areas (arrows) of rats treated with antisense oligonucleotide (E), compared with control rats injected with either saline (C) or sense oligonucleotide to µ-calpain (D). Original magnification 450x. Three rats were studied in each group.

 
These data demonstrate the efficacy and specificity of µ-calpain antisense ODN therapy for suppressing µ-calpain expression in the rat mesenteric microcirculation.

We also studied the effect of systemic calpain inhibition on urinary albumin excretion. Data reported in Table 1 demonstrate that ZDF rats have elevated albuminuria when compared with nondiabetic ZL rats. A 4-day treatment with the calpain inhibitor ZLLal significantly attenuated albuminuria in ZDF rats, albeit urinary albumin levels remained significantly elevated when compared with control ZL rats.


View this table:
[in this window]
[in a new window]

  		TABLE 1 The effect of calpain inhibition on urinary albumin excretion

 
These data are consistent with those obtained in the mesenteric microcirculation and they further demonstrate the mechanistic contribution of calpain to the dysfunction of organs that witness important diabetes complications.

We also measured mean arterial blood pressure, blood flow, vessel diameter, vascular density, and leukocyte-endothelium interactions since they are important determinants of vascular permeability in vivo. No significant differences were observed in mean arterial blood pressure, vessel diameter, and vascular density under our experimental conditions (data not shown).

However, we found that calculated shear rate values in postcapillary venules of ZDF rat mesenteries were significantly decreased, despite remaining within physiologic range (Fig. 3A). This finding is in agreement with previous studies, demonstrating decreased shear rate values in the microcirculation of diabetic rats (28). These data indicate that the changes in albumin permeability seen in the microvasculature of ZDF rats are unlikely driven by abrupt alterations in hydrostatic pressures or vascular density.


Figure 3
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 3. Venular shear rate values are significantly reduced by hyperglycemia. A: Wall shear rate values were measured during IVM studies in mesenteric postcapillary venules of nondiabetic ZL ({blacksquare}) and diabetic ZDF ({square}) rats. Venular shear rates were significantly reduced in diabetic ZDF rats, albeit still found in the physiological range. No changes in venular shear rates were seen after the inhibition of calpain activity or its antisense depletion, indicating that inhibition of calpain does not affect blood flow velocity or vessel diameter in postcapillary venules. B: Baseline numbers of adherent leukocytes in all experimental groups of rats were quantified during IVM. Inhibition of calpain activity significantly attenuates leukocyte adhesion and extravasation in the diabetic microcirculation of ZDF rats. Data are expressed as means ± SEM. n = 6–8 rats (average) in each group.

 
In contrast, we found evidence of increased leukocyte adhesion in the microcirculation of ZDF rats. In particular, leukocyte adhesion was increased sixfold in postcapillary venules of ZDF rats (P < 0.01 vs. ZL), a value which was equally attenuated by antisense depletion of µ-calpain and pharmacological inhibition of calpain activity (Fig. 3B).

Hyperglycemia and albumin permeability.
Albeit hyperglycemia is the most distinguished feature of ZDF rats, one must consider the possibility that complex metabolic alterations, and not hyperglycemia alone, can, in theory, play a role in the observed albumin hypermeability of ZDF rats. To answer this important question, we exposed the mesenteric microcirculation of nondiabetic ZL rats to glucose levels comparable with those found in ZDF rats. Figure 4 demonstrates that acute experimental hyperglycemia increases albumin leakage in nondiabetic postcapillary venules. The effects of D-glucose could not be attributed to changes in ambient osmolarity, as demonstrated by the fact that intraperitoneal administration of 25 mmol/l L-glucose did not increase albumin permeability (Fig. 4).


Figure 4
View larger version (20K):
[in this window]
[in a new window]

  		FIG. 4. Elevated ambient glucose increases albumin permeability in the nondiabetic microvasculature of ZL rats. The average permeability index to Texas Red–labeled albumin was calculated during IVM studies in mesenteric postcapillary venules of all experimental groups of ZL rats. A 12-h exposure of the mesenteric microcirculation to D-glucose, but not L-glucose, increases albumin permeability in a calpain-dependent manner. Depletion of circulating PMN leukocytes with antineutrophil serum (ANS) only marginally attenuated the increase in vascular permeability induced by D-glucose (P > 0.05). In contrast, albumin permeability values were nearly normalized following inhibition of calpain activity. Data are expressed as means ± SEM. n = 6–8 rats (average) in each group.

 
Thereafter, we studied whether the hypermeability response to acute experimental hyperglycemia was also calpain dependent. Figure 4 demonstrates that pharmacological inhibition of calpain activity completely prevented the increase in albumin permeability in response to D-glucose. Taken together, these data indicate that hyperglycemia alone is able to causes a calpain-dependent alteration of the endothelial cell barrier, which results in extravasation of circulating macromolecules into organ tissue.

Role of leukocytes in the vascular permeability of hyperglycemia.
Leukocyte adhesion is an important determinant of vascular permeability in inflamed vessels. It is also widely accepted that PMN leukocytes are the leukocyte population largely responsible for increased albumin leakage in inflamed microvascular networks (29). We have demonstrated that increased leukocyte adhesion occurs in response to acute experimental hyperglycemia and diabetes and that this phenomenon is prevented by calpain inhibition (9,10). Accordingly, we embarked in further studies to understand whether the beneficial effect of calpain inhibition on microvascular permeability is secondary to its inhibitory action on PMN's adhesion.

The circulating pool of PMNs was depleted in control rats and rats injected with 25 mmol/l D-glucose by intraperitoneal injection of antineutrophil serum. Following antineutrophil serum treatment, the number of circulating leukocytes was consistently reduced from the average value of 1,900 ± 70 PMNs/µl to 197 ± 41 PMNs/µl (P < 0.01).

The effects of acute PMN depletion on leukocyte adhesion and albumin permeability in the hyperglycemic microcirculation were then studied by IVM. There was a marginal, but significant, attenuation of the basal vascular permeability following PMN depletion in control rats given antineutrophil serum alone (Fig. 4). This protective effect of antineutrophil serum on baseline vascular permeability is likely due to the prevention of nonspecific changes in the endothelial cell barrier caused by minimal activation of PMNs during the surgical procedures required for IVM. In contrast, acute elevation in ambient glucose dramatically increased vascular permeability (Fig. 4) and leukocyte adhesion (Fig. 5) in the microvasculature to levels comparable with those seen in chronically hyperglycemic ZDF rats (Figs. 1 and 3).


Figure 5
View larger version (16K):
[in this window]
[in a new window]

  		FIG. 5. Elevated ambient glucose increases the adhesion of circulating PMN leukocytes in the microcirculation of ZL rats. D-glucose levels in the range of those found in spontaneously hyperglycemic ZDF rats significantly increase the number of PMN leukocytes firmly adhering to the vascular endothelium of the microvasculature. Glucose-induced leukocyte adhesion was inhibited by calpain inhibition and PMN leukocyte depletion with antineutrophil serum (ANS). Data are expressed as means ± SEM. n = 6–8 rats (average) in each group.

 
Leukocyte adhesion induced by D-glucose was drastically reduced by depletion of circulating PMNs, confirming previous observations that PMNs are the predominant leukocyte population that adheres in hyperglycemic microvascular networks, at least as seen by IVM (30) (Fig. 5). Of interest, the effect of high glucose on albumin permeability largely persisted even in the absence of adhered PMN (Fig. 4), which suggests that the vascular endothelium is a primary direct target of hyperglycemia. Similar results were observed following depletion of circulating leukocytes in ZDF rats (data not shown).

These data further support the hypothesis that activation of calpain activity in hyperglycemia is responsible for primary alteration in the endothelial cell barrier, independent of overt neutrophil adhesion.


   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Increased permeability to macromolecules is a well-described alteration of the diabetic microvasculature, which, along with inflammation, is causative of diabetes complications. Our data demonstrate that hyperglycemia increases albumin permeability via a µ-calpain–dependent mechanism, independent of overt leukocyte adhesion.

The calpain system is a newly emerging signaling pathway in diabetic vascular disease. The gene encoding calpain-10 has now been associated with subclinical atherosclerosis in insulin-resistant humans (31). Studies have also demonstrated a role for calpains in key processes of inflammatory vascular remodeling, such as vascular smooth cell proliferation and migration (32) and platelet activation (33). We have recently reported that acute and chronic hyperglycemia increases leukocyte adhesion to the vascular endothelium of postcapillary venules and decreases nitric oxide production via a µ-calpain–dependent mechanism (9,10); calpain inhibition prevents these actions and stabilizes basal levels of nitric oxide in the face of hyperglycemia and diabetes. Others have demonstrated that inhibition of calpain activity corrects endothelial dysfunction and penile nitrergic dysfunction in diabetic mice (11). Relevant to organ injury, overexpression of the endogenous calpain inhibitor calpastatin ameliorates renal injury and failure in diabetes (34). Finally, calpain has been implicated in the impaired nerve regenerations of hyperglycemic rats (12).

This study was undertaken to test whether calpain is implicated in the hypermeability of the hyperglycemic vasculature. Increased vascular permeability is commonly found in hyperglycemic vascular beds, and transcapillary escape of albumin is related to blood glucose control (35). Increased albumin permeability is a very early consequence of endothelial dysfunction in the diabetic retina (36), kidney (37), and rat mesentery (38). Overall, enhanced endothelial permeability leads to extravasation of plasma and macromolecules into the adjacent interstitial compartment. Chronic extravasation of albumin modifies the size and composition of the interstitium, which causes disturbances in the traffic of fluid and vital substrates to the cellular mass and in the removal of waste products in the opposite direction (6). Accordingly, capillary leakage contributes to the increased susceptibility to local and systemic injury of diabetic organs (39).

In the present study, we found evidence of a mechanistic link between µ-calpain activity and albumin extravasation in the hyperglycemic microcirculation. One particularly intriguing aspect of our results is the fact that the effect of hyperglycemia on albumin permeability was found to be independent of leukocyte adhesion. It is widely accepted that the adhesion of leukocytes to the vascular endothelium is almost invariably associated with increased vascular permeability (40). Leukocyte adhesion is increased by hyperglycemia and diabetes (9,41). Inhibition of calpain activity prevents adhesion of leukocytes in the hyperglycemic microcirculation (10). Thus, it was reasonable to expect that the effect of calpain inhibition on vascular permeability would be secondary to reduced leukocyte-endothelium interactions. To the contrary, we found that leukocytes adhesion did not play an obligatory role in the albumin hyperpermeability of the hyperglycemic vasculature. Nonetheless, it should be noted that our study tested only the impact of acute neutrophil depletion on the hyperpermeability of the hyperglycemic vasculature. Thus, our results cannot entirely rule out the possibility that neutrophil-derived mediators that could have become bound to the vascular endothelium were, in part, still responsible for sustained experimental activation and vascular hyperpermeability under our experimental conditions. In support of this view, recent work has emphasized a role for endothelial-bound neutrophil-derived myeloperoxidase in the mechanism of endothelial dysfunction in humans with cardiovascular disease (42).

Under normal and pathologic conditions, several signaling pathways regulate the permeability of the vascular endothelium, and they have been recently reviewed by Mehta et al. (43). Relevant to diabetes, future research should focus on the roles of protein kinase C (PKC) and endothelial nitric oxide because of their relevance to vascular complications. In fact, several studies have implicated a role for PKC in the hyperpermeability of diabetes (44–46), and others have demonstrated the existence of cross-talk regulation between calpain and PKC (47).

The role of endothelial nitric oxide in the modulation of vascular permeability still remains controversial (43). However, recent work has suggested that basal endothelial nitric oxide is necessary to prevent albumin leakage through the vascular endothelium (48). Interestingly, we have reported that calpain reduces basal availability of endothelial nitric oxide in experimental hyperglycemia and diabetes (9,10). Overall, very little is available in scientific literature on the role of calpains in the regulation of endothelial cell barrier. Two recent studies have reported that under physiologic conditions, baseline µ-calpain activity is important in maintaining the integrity of the endothelial cell barrier (15), whereas in vascular inflammation, increased calpain activity increases endothelial permeability (14). Obviously, further studies are needed to fully understand the molecular mechanism by which calpain increases vascular permeability during hyperglycemia and diabetes.

In terms of clinical application, albuminuria is now considered an independent risk marker for macro- and microvascular complications in diabetes (7). It has been hypothesized that loss of albumin through the kidneys reflects a generalized status of endothelial cell dysfunction in the hyperglycemic patient (49), acting through increased levels of biomarkers of inflammation (50). Conversely, decreasing albumin leakage is associated with improving cardiovascular and renal outcomes in diabetic patients (7). Our results support this view by demonstrating that a widespread calpain-dependent increase in albumin leakage occurs both in splanchnic circulation and in the kidney. Accordingly, calpains could represent an important molecular marker and pharmacological target for the prevention and treatment of diabetic vascular complications.

We have provided evidence that the inhibition of calpain activity attenuates the vascular hypermeability associated with acute and chronic hyperglycemia. These findings uncover a role for the calcium-dependent protease calpain in the pathophysiology of diabetic vascular disease.


   ACKNOWLEDGMENTS
 
This study was supported by the National Institutes of Health Grant 1R01DK064344 and an American Diabetes Association Grant 7-02-RA-79 (to R.S.).


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on 19 April 2007. DOI: 10.2337/db06-1198.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db06-1198.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication August 29, 2006 and accepted in revised form April 10, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Dandona P, Aljada A, Chaudhuri A, Mohanty P: Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 5:189–197, 2004[Medline]
  2. Lteif AA, Han K, Mather KJ: Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112:32–38, 2005[Abstract/Free Full Text]
  3. Dang L, Seale JP, Qu X: High glucose-induced human umbilical vein endothelial cell hyperpermeability is dependent on protein kinase C activation and independent of the Ca2+-nitric oxide signalling pathway. Clin Exp Pharmacol Physiol 32:771–776, 2005[Medline]
  4. Algenstaedt P, Schaefer C, Biermann T, Hamann A, Schwarzloh B, Greten H, Ruther W, Hansen-Algenstaedt N: Microvascular alterations in diabetic mice correlate with level of hyperglycemia. Diabetes 52:542–549, 2003[Abstract/Free Full Text]
  5. Bonnardel-Phu E, Wautier JL, Schmidt AM, Avila C, Vicaut E: Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes 48:2052–2058, 1999[Abstract]
  6. Plante GE, Chakir M, Lehoux S, Lortie M: Disorders of body fluid balance: a new look into the mechanisms of disease. Can J Cardiol 11:788–802, 1995[Medline]
  7. Basi S, Lewis JB: Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 47:927–946, 2006[Medline]
  8. Goll DE, Thompson VF, Li H, Wei W, Cong J: The calpain system. Physiol Rev 83:731–801, 2003[Abstract/Free Full Text]
  9. Stalker TJ, Gong Y, Scalia R: The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 54:1132–1140, 2005[Abstract/Free Full Text]
  10. Stalker TJ, Skvarka CB, Scalia R: A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J 17:1511–1513, 2003[Abstract/Free Full Text]
  11. Nangle MR, Cotter MA, Cameron NE: The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice. Eur J Pharmacol 538:148–153, 2006[Medline]
  12. Terada M, Yasuda H, Kikkawa R: Delayed Wallerian degeneration and increased neurofilament phosphorylation in sciatic nerves of rats with streptozocin-induced diabetes. J Neurol Sci 155:23–30, 1998[Medline]
  13. McDonald MC, Mota-Filipe H, Paul A, Cuzzocrea S, Abdelrahman M, Harwood S, Plevin R, Chatterjee PK, Yaqoob MM, Thiemermann C: Calpain inhibitor I reduces the activation of nuclear factor-kappaB and organ injury/dysfunction in hemorrhagic shock. FASEB J 15:171–186, 2001[Abstract/Free Full Text]
  14. Bernhard D, Csordas A, Henderson B, Rossmann A, Kind M, Wick G: Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules. FASEB J 19:1096–1107, 2005[Abstract/Free Full Text]
  15. Gonscherowski V, Becker BF, Moroder L, Motrescu E, Gil-Parrado S, Gloe T, Keller M, Zahler S: Calpains: a physiological regulator of the endothelial barrier? Am J Physiol Heart Circ Physiol 290:H2035–H2042, 2006[Abstract/Free Full Text]
  16. Peterson RG: The zucker diabetic fatty (ZDF) rat. In Animal Models of Diabetes: A Primer. Sharif E, Ed. Newark, NJ, Hardwood Academic Publisher, 2001, p.109–128
  17. St-Pierre P, Bouffard L, Papirakis ME, Maheux P: Increased extravasation of macromolecules in skeletal muscles of the Zucker rat model. Obesity 14:787–793, 2006[Medline]
  18. Bohlen HG, Hankins KD: Early arteriolar and capillary changes in streptozotocin-induced diabetic rats and intraperitoneal hyperglycaemic rats. Diabetologia 22:344–348, 1982[Medline]
  19. Booth G, Stalker TJ, Lefer AM, Scalia R: Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab 280:E848–E856, 2001[Abstract/Free Full Text]
  20. Smith ML, Long DS, Damiano ER, Ley K: Near-wall micro-PIV reveals a hydrodynamically relevant endothelial surface layer in venules in vivo. Biophys J 85:637–645, 2003[Medline]
  21. De Vriese AS, Tilton RG, Stephan CC, Lameire NH: Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12:1734–1741, 2001[Abstract/Free Full Text]
  22. Kurose I, Anderson DC, Miyasaka M, Tamatani T, Paulson JC, Todd RF, Rusche JR, Granger DN: Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res 74:336–343, 1994[Abstract/Free Full Text]
  23. Guttmann RP, Johns RA: Measurement of calpain activity in vitru and in situ using a fluorescent compund and tau as substrates. In Calpain Methods and Protocols John SE, Ed. Totowa, NJ, Humana Press, 2000, p.143–150
  24. Sultan KR, Dittrich BT, Pette D: Calpain activity in fast, slow, transforming, and regenerating skeletal muscles of rat. Am J Physiol Cell Physiol 279:C639–C647, 2000[Abstract/Free Full Text]
  25. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S: Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo) 119:572–576, 1996[Abstract/Free Full Text]
  26. Johnston B, Burns AR, Suematsu M, Issekutz TB, Woodman RC, Kubes P: Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. J Clin Invest 103:1269–1276, 1999[Medline]
  27. Fujitani K, Kambayashi J, Sakon M, Ohmi SI, Kawashima S, Yukawa M, Yano Y, Miyoshi H, Ikeda M, Shinoki N, Monden M: Identification of mu-, m-calpains and calpastatin and capture of mu-calpain activation in endothelial cells. J Cell Biochem 66:197–209, 1997[Medline]
  28. Panes J, Kurose I, Rodriguez-Vaca D, Anderson DC, Miyasaka M, Tso P, Granger DN: Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation 93:161–167, 1996[Abstract/Free Full Text]
  29. Wedmore CV, Williams TJ: Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289:646–650, 1981[Medline]
  30. Tangelder GJ, Janssens CJ, Slaaf DW, oude Egbrink MG, Reneman RS: In vivo differentiation of leukocytes rolling in mesenteric postcapillary venules. Am J Physiol 268:H909–H915, 1995[Medline]
  31. Goodarzi MO, Taylor KD, Guo X, Quinones MJ, Cui J, Li Y, Saad MF, Yang H, Hsueh WA, Hodis HN, Rotter JI: Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study. Diabetes 54:1228–1232, 2005[Abstract/Free Full Text]
  32. Paulhe F, Bogyo A, Chap H, Perret B, Racaud-Sultan C: Vascular smooth muscle cell spreading onto fibrinogen is regulated by calpains and phospholipase C. Biochem Biophys Res Commun 288:875–881, 2001[Medline]
  33. Croce K, Flaumenhaft R, Rivers M, Furie B, Furie BC, Herman IM, Potter DA: Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem 274:36321–36327, 1999[Abstract/Free Full Text]
  34. Dnyanmote AV, Sawant SP, Lock EA, Latendresse JR, Warbritton AA, Mehendale HM: Calpastatin overexpression prevents progression of S-1,2-dichlorovinyl-l-cysteine (DCVC)-initiated acute renal injury and renal failure (ARF) in diabetes. Toxicol Appl Pharmacol 215:146–157, 2006[Medline]
  35. Parving HH, Noer I, Deckert T, Evrin PE, Nielsen SL, Lyngsoe J, Mogensen CE, Rorth M, Svendsen PA, Trap-Jensen J, Lassen NA: The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetics. Diabetologia 12:161–166, 1976[Medline]
  36. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW, Penn State Retina Research Group: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47:1953–1959, 1998[Abstract]
  37. Pinter GG, Lightman SL, Wilson PD, Yuen L, Bradbury MW: Albumin escape from microvessels in kidney, heart and skeletal muscle in experimental diabetes mellitus in the anaesthetized rat. Exp Physiol 76:899–904, 1991[Abstract]
  38. Arshi K, Bendayan M, Ghitescu LD: Alterations of the rat mesentery vasculature in experimental diabetes. Lab Invest 80:1171–1184, 2000[Medline]
  39. Lawson S, Ward DT, Conner C, Gallagher C, Tsokos G, Shea-Donohue T: Diabetic hyperglycemia: a facilitating factor in systemic capillary leak. J Surg Res 105:95–101, 2002[Medline]
  40. Huxley V, Rumbaut RE: Microvascular permeability in inflammation. In Physiology of Inflammation. Ley K, Ed. New York, Oxford University Press, 2001, p.65–79
  41. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905–1915, 1998[Medline]
  42. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, Sydow K, Lau D, Szocs K, Klinke A, Kubala L, Berglund L, Schrepfer S, Deuse T, Haddad M, Risius T, Klemm H, Reichenspurner HC, Meinertz T, Heitzer T: Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113:1871–1878, 2006[Abstract/Free Full Text]
  43. Mehta D, Malik AB: Signaling mechanisms regulating endothelial permeability. Physiol Rev 86:279–367, 2006[Abstract/Free Full Text]
  44. Yuan SY, Ustinova EE, Wu MH, Tinsley JH, Xu W, Korompai FL, Taulman AC: Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87:412–417, 2000[Abstract/Free Full Text]
  45. Park JY, Ha SW, King GL: The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit Dial Int 19 (Suppl. 2):S222–S227, 1999
  46. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866, 1998[Abstract]
  47. Sato K, Kawashima S: Calpain function in the modulation of signal transduction molecules. Biol Chem 382:743–751, 2001[Medline]
  48. Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, Malik AB: Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol 289:L371–L381, 2005[Abstract/Free Full Text]
  49. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32:219–226, 1989[Medline]
  50. Ritz E: Renal dysfunction as a novel risk factor: microalbuminuria and cardiovascular risk. Kidney Int 93:S25–S28, 2005

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db06-1198v1
db06-1198v2
db06-1198v3
56/7/1842    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scalia, R.
Right arrow Articles by Sharma, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scalia, R.
Right arrow Articles by Sharma, K.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum